search
Back to results

A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension

Primary Purpose

Hypertension

Status
Withdrawn
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Cardene® I.V.
Sponsored by
Facet Biotech
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, High Blood Pressure, Pediatric Hypertension, High blood pressure in children

Eligibility Criteria

2 Years - 16 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Evidence of Stage 1 or Stage 2 systolic hypertension at the time of screening.
  • Male or female subjects, ages ≥2 to ≤16 years.
  • Females who meet either of the following criteria:

    • Non-childbearing potential , as documented by:

      1. a medical history of non-menstruation or
      2. surgical sterility from oophorectomy and/or hysterectomy. * A history of tubal ligation or evidence of a sterile sexual partner is insufficient evidence of non-childbearing potential.
    • Childbearing potential: provide a negative urine pregnancy test within 24 hours of administration of study drug and agree to utilize effective contraception or remain abstinent during the entire treatment and follow-up periods of the study.
  • Signed informed consent provided by an authorized subject representative and assent from subject, if feasible (based on local Institutional Review Board (IRB)/ethics panel requirements).

Exclusion Criteria:

  • Subjects with seizures, altered state of consciousness, chest pain, facial palsy or intracranial hemorrhage at the time of screening.
  • Receiving antihypertensive medication within a duration specified prior to screening.
  • Treatment with cimetidine within 10 hours prior to dosing with study drug.
  • Any known or suspected allergy to nicardipine hydrochloride.
  • A calculated Glomerular Filtration Rate (GFR) under 30 mL/min/ 1.73 m2 as calculated using the Schwartz formula and the associated K values.
  • Known history of severe aortic stenosis.
  • Known history of severe left ventricular dysfunction.
  • Known history of severely impaired hepatic function with portal hypertension.
  • Liver function test (AST or ALT) results greater than or equal to twice the upper limit of normal.
  • Receiving maintenance hemodialysis at screening or anticipated to require hemodialysis within 12 hours following initiation of treatment with study drug.
  • Receiving a blood transfusion at screening or anticipated to require blood transfusions within 12 hours following initiation of treatment with study drug.
  • Lack of appropriate intravenous (I.V.) access.
  • Inability to tolerate a large-volume I.V. infusion.
  • Any other condition or prior therapy, which, in the opinion of the investigator, would make the subject unsuitable for this study.
  • Participation in any phase of another clinical research study involving the evaluation of another investigational drug or device within 30 days before randomization.

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Placebo Comparator

Experimental

Experimental

Experimental

Arm Label

1

2

3

4

Arm Description

5 mcg

2.5

0.5

Outcomes

Primary Outcome Measures

Mean percent change in SBP (Systolic Blood Pressure) from baseline during the 30-minute Randomized, Placebo-controlled Infusion Phase for each dose level of Cardene I.V. compared to placebo.

Secondary Outcome Measures

1) Mean percent change in SBP and DBP between various phases of dosing. 2) Proportion of subjects requiring additional antihypertensive medications during the treatment period. 3) Mean effective dose of Cardene I.V.

Full Information

First Posted
September 10, 2007
Last Updated
March 15, 2012
Sponsor
Facet Biotech
search

1. Study Identification

Unique Protocol Identification Number
NCT00528827
Brief Title
A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension
Official Title
A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
March 2012
Overall Recruitment Status
Withdrawn
Why Stopped
Due to the sale of Cardene IV, the sponsor has stopped enrollment and withdrawn the study. No safety issues were identified.
Study Start Date
September 2007 (undefined)
Primary Completion Date
December 2008 (Actual)
Study Completion Date
December 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Facet Biotech

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To define the relationship between Cardene I.V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension.
Detailed Description
Children with acute hypertensive episodes are frequently treated with the same marketed drugs as adults. Few drugs are specifically indicated for use in children with severe hypertension. Cardene I.V. has been widely used in children with severe hypertension without specific dosing recommendations for children in the labeling. This study is designed to examine the pharmacokinetics, pharmacodynamics, safety, and efficacy of using Cardene I.V. to reduce blood pressure (BP) in children with hypertension and will provide important information to guide use in pediatric patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, High Blood Pressure, Pediatric Hypertension, High blood pressure in children

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Placebo Comparator
Arm Title
2
Arm Type
Experimental
Arm Description
5 mcg
Arm Title
3
Arm Type
Experimental
Arm Description
2.5
Arm Title
4
Arm Type
Experimental
Arm Description
0.5
Intervention Type
Drug
Intervention Name(s)
Cardene® I.V.
Intervention Description
5 mcg/kg/min Cardene I.V. 2.5 mcg/kg/min Cardene I.V. 0.5 mcg/kg/min Cardene I.V.
Primary Outcome Measure Information:
Title
Mean percent change in SBP (Systolic Blood Pressure) from baseline during the 30-minute Randomized, Placebo-controlled Infusion Phase for each dose level of Cardene I.V. compared to placebo.
Time Frame
30 minutes
Secondary Outcome Measure Information:
Title
1) Mean percent change in SBP and DBP between various phases of dosing. 2) Proportion of subjects requiring additional antihypertensive medications during the treatment period. 3) Mean effective dose of Cardene I.V.
Time Frame
72

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Evidence of Stage 1 or Stage 2 systolic hypertension at the time of screening. Male or female subjects, ages ≥2 to ≤16 years. Females who meet either of the following criteria: Non-childbearing potential , as documented by: a medical history of non-menstruation or surgical sterility from oophorectomy and/or hysterectomy. * A history of tubal ligation or evidence of a sterile sexual partner is insufficient evidence of non-childbearing potential. Childbearing potential: provide a negative urine pregnancy test within 24 hours of administration of study drug and agree to utilize effective contraception or remain abstinent during the entire treatment and follow-up periods of the study. Signed informed consent provided by an authorized subject representative and assent from subject, if feasible (based on local Institutional Review Board (IRB)/ethics panel requirements). Exclusion Criteria: Subjects with seizures, altered state of consciousness, chest pain, facial palsy or intracranial hemorrhage at the time of screening. Receiving antihypertensive medication within a duration specified prior to screening. Treatment with cimetidine within 10 hours prior to dosing with study drug. Any known or suspected allergy to nicardipine hydrochloride. A calculated Glomerular Filtration Rate (GFR) under 30 mL/min/ 1.73 m2 as calculated using the Schwartz formula and the associated K values. Known history of severe aortic stenosis. Known history of severe left ventricular dysfunction. Known history of severely impaired hepatic function with portal hypertension. Liver function test (AST or ALT) results greater than or equal to twice the upper limit of normal. Receiving maintenance hemodialysis at screening or anticipated to require hemodialysis within 12 hours following initiation of treatment with study drug. Receiving a blood transfusion at screening or anticipated to require blood transfusions within 12 hours following initiation of treatment with study drug. Lack of appropriate intravenous (I.V.) access. Inability to tolerate a large-volume I.V. infusion. Any other condition or prior therapy, which, in the opinion of the investigator, would make the subject unsuitable for this study. Participation in any phase of another clinical research study involving the evaluation of another investigational drug or device within 30 days before randomization.
Facility Information:
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90211
Country
United States
City
Miami
State/Province
Florida
ZIP/Postal Code
33145
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension

We'll reach out to this number within 24 hrs